Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID
Launched by TAIPEI VETERANS GENERAL HOSPITAL, TAIWAN · Apr 3, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a specific probiotic, Lactobacillus Paracasei PS23, can help improve "brain fog" symptoms in people experiencing Long COVID. Long COVID refers to ongoing health issues that some individuals face after recovering from the initial COVID-19 infection, which can include problems with thinking and memory, often described as brain fog. The trial will involve participants taking either the probiotic or a placebo (a capsule without active ingredients) for two months. Researchers will assess changes in symptoms and cognitive function using questionnaires and tests before and after the study period.
To be eligible for this trial, participants must be between 20 and 80 years old, have had a confirmed SARS-CoV-2 infection, and report symptoms of brain fog. They should also have a certain score on a cognitive test called the MoCA, which measures thinking abilities. Importantly, people with other serious health conditions affecting their brain or digestive system, or those currently taking certain medications, may not qualify. Participants can expect regular check-ins and tests to monitor their progress throughout the study. This trial is not yet recruiting, but it aims to find out if probiotics could be a helpful treatment for those struggling with cognitive changes after COVID-19.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20 to 80 year old
- • had been infected by SARS-CoV-2
- • Stable vital signs
- • Have brain fog conplaint
- • MoCA\<30 at baseline
- Exclusion Criteria:
- • refuse to join the study or refuse to sign the Informed Consent Form
- • have other neurological disease that may affect cognitive function, such as Parkinson disease, Seizure, etc.
- • have other gastrointestinal disease that may affect cognitive function, including tumors.
- • severe hearing loss or visual loss that may hinder cognitive function tests
- • Taken anti-seizure drug in 7 days.
- • Already taking probiotics supplement regularly
- • Taken antibiotics in two weeks
- • taking stool softener or laxative regularly
- • have valvular heart disease
- • have congenital or acquired immunodeficiency or is under iimmunosuppressant therapy
- • Pregnant or plans to be pregnant
- • BMI\>30
- • Have been performed severe gastrointestinal surgery(s)
- • Severe liver, kidney, cardiovascular, hematologic or metabolic disorder
- • In critical condition
About Taipei Veterans General Hospital, Taiwan
Taipei Veterans General Hospital, located in Taiwan, is a renowned medical institution dedicated to providing comprehensive healthcare and advancing medical research. As a prominent clinical trial sponsor, the hospital is committed to exploring innovative therapies and improving patient outcomes through rigorous scientific studies. With a multidisciplinary team of experienced researchers and clinicians, Taipei Veterans General Hospital prioritizes ethical standards and patient safety while contributing to the global medical community's knowledge base. Its state-of-the-art facilities and collaborative environment foster groundbreaking research that aims to address pressing healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported